

0002007191-25-0000176-K Telix Pharmaceuticals Ltd 2025021320250213080945080946080946 0 0002007191-25-000017 6-K 3 20250212 20250213 20250213 Telix Pharmaceuticals Ltd 0002007191 2834 000000000 C3 1231 6-K 34 001-42128 25617294 55 FLEMINGTON ROAD NORTH MELBOURNE C3 3051 61 3 9093 3855 55 FLEMINGTON ROAD NORTH MELBOURNE C3 3051 6-K 1 f6-kukilluccix.htm CURRENT REPORT OF FOREIGN ISSUER PURSUANT TO RULES 13A-16 AND 15D-16 AMENDMENTS Â UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Â FORM 6-K Â REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 Â For the month of February, 2025 Â Commission File Number: 001-42128 Â Telix Pharmaceuticals Limited (Translation of registrantâ€™s name into English) Â 55 Flemington Road North Melbourne, Victoria 3051, Australia (Address of principal executive offices) Â Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Â Form 20-F â~ Form 40-F â~ Â INFORMATION CONTAINED IN THIS FORM 6-K REPORT Â On February 13, 2025 (Melbourne, Australia), Telix Pharmaceuticals Limited filed with the Australian Securities Exchange an announcement captioned âœœIlluccix Approved in the United Kingdom,â€ a copy of which is attached to this Form 6-K as Exhibit 99.1. Â 99.1 Press release âœ February 13, 2025 Â SIGNATURES Â Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Â Â Â Â Â Telix Pharmaceuticals Limited Â Â Â Date: February 13, 2025 By: /s/ Genevieve Ryan Â Â Name: Genevieve Ryan Â Â Title: Company Secretary Â Â Â Â EX-99.1 2 prilluccixuk.htm EX-99.1 Telix Pharmaceuticals LimitedACN 616 620 369 55 Flemington Road North Melbourne Victoria, 3051 Australia Â ASX ANNOUNCEMENT Â Â IlluccixÂ® Approved in the United Kingdom Â Melbourne (Australia) âœ 13 February 2025. Telix Pharmaceuticals Limited (ASX: TLX, Nasdaq: TLX, Telix, the Company) today announces that the United Kingdom (UK) Medicines and Healthcare Products Regulatory Agency (MHRA) has approved the Marketing Authorization Application (MAA) for its prostate cancer PET1 imaging agent IlluccixÂ® (kit for the preparation of gallium-68 gozetotide injection). Illuccix is indicated in the UK for the detection and localization of prostate-specific membrane antigen (PSMA)-positive lesions in adults with prostate cancer, using PET. PSMA-PET imaging2 represents a major advancement in prostate cancer management, largely replacing conventional imaging methods (bone scan, CT3 scan) as the standard of care after initial diagnosis and biochemical recurrence (BCR). Global guidelines highlight the superior accuracy of PSMA-PET for the staging of primary disease and evaluation of BCR/biochemical persistence (BCP)4. Gary Cook, MD, Professor of Molecular Imaging at Kings College London School of Biomedical Engineering & Imaging Sciences, commented, âœœPSMA-PET supply shortages in the UK and Europe have escalated over the past 12 months as demand increases, which has led to delays for men in urgent need of a scan to direct clinical management. It is great news that Telix can now help address this unmet need and improve equity of access in the UK through their Illuccix imaging agent and network distribution model.â€ RaphaÃ«l Ortiz, Chief Executive Officer, Telix International added, âœœPSMA-PET imaging is one of the most important developments in prostate cancer detection in recent years and we are delighted that we can now bring Illuccix to physicians and their patients across the UK. A key advantage of Illuccix is that the radioisotope (gallium-68) can be produced using a generator locally, taking just a few minutes with minimal equipment. Reliable service delivery combined with greater scheduling flexibility, including in non-metropolitan locations, will benefit patients, physicians and clinical sites in the UK.â€ Illuccix will be made available in the UK through Telixâ€™s exclusive distribution partner, Xiel Limited, a specialist distributor of nuclear medicine, radiotherapy and diagnostic radiology technologies across the UK and Ireland. To order or enquire about Illuccix availability, UK healthcare professionals can email: radiopharm@xiel.co.ukÂ or call +44 (0)1749 372217. Â About IlluccixÂ®â€ Â Telixâ€™s prostate imaging product, gallium-68 (68Ga) gozetotide injection (also known as 68Ga PSMA-11Â and marketed under the brand name IlluccixÂ®), has been approved by the U.S. Food and Drug Administration (FDA)5, by the Australian Therapeutic Goods Administration (TGA)6, by Health Â 1Â Positron emission tomography. 2 Imaging of prostate-specific membrane antigen with positron emission tomography. 3 Computed tomography. 4Â EAU Guidelines. Edn. presented at the EAU Annual Congress Paris 2024. ISBN 978-94-92671-23-3.: <https://uroweb.org/guidelines/prostate-cancer>;Â Â Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. 2023: <https://www.esmo.org/guidelines/guidelines-by-topic/esmo-clinical-practice-guidelines-genitourinary-cancers/clinical-practice-guidelines-prostate-cancer/eupdate-prostate-cancer-treatment-recommendations> 5Â Telix ASX disclosure 20 December 2021. Â Â Page 1 Canada7, by the Danish Medicines Agency8, and by the UK MHRA. Illuccix is currently in national approval review in 19 European countries following a positive decentralized procedure (DCP) opinion by BfArM9. Â About Telix Pharmaceuticals Limited Telix is a biopharmaceutical company focused on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals and associated medical technologies. Telix is headquartered in Melbourne, Australia, with international operations in the United States, Canada, Europe (Belgium and Switzerland), and Japan. Telix is developing a portfolio of clinical and commercial stage products that aims to address significant unmet medical needs in oncology and rare diseases. ARTMS, IsoTherapeutics, Lightpoint, Optimal Tracers and RLS are Telix Group companies. Telix is listed on the Australian Securities Exchange (ASX: TLX) and the Nasdaq Global Select Market (Nasdaq: TLX). Telixâ€™s osteomyelitis (bone infection) imaging agent, technetium-99m (99mTc) besilesonab, marketed under the brand name ScintimunÂ®, is approved in 32 European countries and Mexico. Telixâ€™s miniaturized surgical gamma probe, SENSEIÂ®, for minimally invasive and robotic-assisted surgery, is registered with the FDA for use in the U.S. and has attained a Conformit   Europ  enne (CE) Mark for use in the European Economic Area. No other Telix product has received a marketing authorization in any jurisdiction. Visit www.telixpharma.com for further information about Telix, including details of the latest share price, ASX and SEC filings, investor and analyst presentations, news releases, event details and other publications that may be of interest. You can also follow Telix on LinkedIn,Â X and Facebook. Â Telix Investor Relations Ms. Kyahn Williamson Telix Pharmaceuticals Limited SVP Investor Relations and Corporate Communications Email: kyahn.williamson@telixpharma.com Â This announcement has been authorised for release by the Telix Pharmaceuticals Limited Disclosure Committee on behalf of the Board. Legal Notices You should read this announcement together with our risk factors, as disclosed in our most recently filed reports with the Australian Securities Exchange (ASX), U.S. Securities and Exchange Commission (SEC), including our registration statement on Form 20-F filed with the SEC, or on our website. The information contained in this announcement is not intended to be an offer for subscription, invitation or recommendation with respect to securities of Telix Pharmaceuticals Limited (Telix) in any jurisdiction, including the United States. The information and opinions contained in this announcement are subject to change without notification. Â To the maximum extent permitted by law, Telix disclaims any obligation or undertaking to update or revise any information or opinions contained in this announcement, including any forward-

looking statements (as referred to below), whether as a result of new information, future developments, a change in expectations or assumptions, or otherwise. No representation or warranty, express or implied, is made in relation to the accuracy or completeness of the information contained or opinions expressed in the course of this announcement. This announcement may contain forward-looking statements, including within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, that relate to anticipated future events, financial performance, plans, strategies or business developments. Forward-looking statements can generally be identified by the use of words such as “may”, “expect”, “6Â Telix ASX disclosure 2 November 2021. 7Â Telix ASX disclosure 14 October 2022. 8 Telix media release 11 February 2025. 9Â Page 2 “intend”, “plan”, “estimate”, “anticipate”, “believe”, “outlook”, “forecast” and “guidance”, or the negative of these words or other similar terms or expressions. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Forward-looking statements are based on Telix’s good-faith assumptions as to the financial, market, regulatory and other risks and considerations that exist and affect Telix’s business and operations in the future and there can be no assurance that any of the assumptions will prove to be correct. In the context of Telix’s business, forward-looking statements may include, but are not limited to, statements about: the initiation, timing, progress and results of Telix’s preclinical and clinical trials, and Telix’s research and development programs; Telix’s ability to advance product candidates into, enrol and successfully complete, clinical studies, including multi-national clinical trials; the timing or likelihood of regulatory filings and approvals for Telix’s product candidates, manufacturing activities and product marketing activities; Telix’s sales, marketing and distribution and manufacturing capabilities and strategies; the commercialisation of Telix’s product candidates, if or when they have been approved; Telix’s ability to obtain an adequate supply of raw materials at reasonable costs for its products and product candidates; estimates of Telix’s expenses, future revenues and capital requirements; Telix’s financial performance; developments relating to Telix’s competitors and industry; and the pricing and reimbursement of Telix’s product candidates, if and after they have been approved. Telix’s actual results, performance or achievements may be materially different from those which may be expressed or implied by such statements, and the differences may be adverse. Accordingly, you should not place undue reliance on these forward-looking statements. ©2025 Telix Pharmaceuticals Limited. The Telix Pharmaceuticals®, Telix Group company, and Telix product names and logos are trademarks of Telix Pharmaceuticals Limited and its affiliates. All rights reserved. Trademark registration status may vary from country to country. 9Â The German Federal Institute for Drugs and Medical Devices (Bundesinstitut für Arzneimittel und Medizinprodukte). Telix ASX disclosure 17 January 2025. 10Â Page 3 GRAPHIC 3 image1.gif GRAPHIC begin 644 image1.gif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m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

[656@N9TR61I10K&E5,6GW(H8MBGYB M6:2@>!LK1Z.;F)=:1+?AJ,[2J\$;J9"J-I&J1LNJ;5193'\$J5MUZ13BJ1T
M:I]06j?V!Y9ZZH#RI*5W.HH.H6B-EV:F*-H _JHCKJFD-JFDAJI M&TH6:/DL?G9JD?+JIUIF
G@IZW6F%QG&HP:@3*L82CWJF M%SJIM\$JIM7J'K'I7\$, @LF4JDT4FJ@!JJP+J.@3FLK4>8G(IVI2>LS%HUDD%D
MRL&JN _DU'P@3L4JAN)JMMKJMVH5.2@MO=H6R?JKS4JN_<<5X?J,?8J!J3&N
MP7I*U(B7S2&M7 _HU"X43LJM^JJM_+JO4LE)\\$@MZ6J+[UID0#.P]+BN--A^ MIWIVL
BGSD&O=H@36X2@.^&O_9JQ*%NO4%FUFH*PNG2EU_0S(\$L5)7L8"INR MM&QT&>"V"QB.H9&ZNQ-#NS00^J%-
X+B>K%DYZ,CL;%3^;?P4[M"]+B7WQ MB(.G'3 KA3);LTYKLJU%&);BIKB'YAK**,.\$['%%M+246[5E8JBMKEAMRQ
MM"S8M%";MD\J[8GJL;I6M=YGED0;20K3M<5:KHH'BUAKD2@%MSR#%V\$;=-]A MM@:
(MFNKMh@KGSKAG'7KMT9:& U+K#KKN)(JGA+>N]HKK)4\$9H;IG&1L _% MN.3'&8=;NFK[=%]KM(V[MU0ZE>
JDSQE5@G*NNQWGV9+N7R9NL^DAJ\183R MA; CNL%'NHE;O!IK4 _EI,G;[NY\$[B.L5;
(ZQO*#:N\C7LK1K0"O1O%M]@:>) M'L+[>P' 8KKBNZW>JLD2[DLBWB7>T^@8;("(:UY>KU^ZA;K^T8W,;=!1;"Z
M.T?NWE)@4 T,X"[*8H9P\$AKXQI;WDEG]L"!CP.X\$(C/XJ)T!4;J9A(.,
MR[_j6Z,,\$636:KP@S*8'&8'IVV41#IK4:Y5<*Y@,.,&M*Z I_,*6&\,'1)WR MRT%H@:0:O,%CJF>*X(5<(B,< "K!)^63 M,
<6X]G^Z&U1"G+#[Z(T\K)Z96:8 _+&W*-%%\$G+A&O(^1D\1A;YN,;4[HYAI MP<8@=+>L.\$ %190?\$0^B,<[?
*AD*JMEBHG,Q!-G[+1IC'JM T/'6jC 3?S& MN,BS=CS#C^R/ O)Z3*G>\Q"E#RW7KR0UQK*.TH9A[RQY0MLR,/(EI'%
<+S) M116->*RLR%K),LP4K?PY1,?*&16&L5P[X2&A/BS&PBS(.NJCQ\$D9(6RSI_Q6 MWJ/*[7?
+M,S\$R>NDRS%KOQQ>=K+GHN,V@R[D;>IOWRCP4S,C3K,VJQDY', M_)K(\$SD_SAP;UPS-L3RV\ERYUBS-
[#H4W9Q(\U;/4Q,62%N:WB%K@5S.Y)RO M&FJZDJ'.Y#O"ER1'[ZR=F!S-K]K&_@S+NBS+/3'1_(9^SQ-8&'!VS&7YBS*
M/7K.I6R7D<'0DFK\$751.\$>T< 1W/-/^59X1TS^!TQ%1TZ7ZHA _=1R&]M]=Q MT"6]H2>=TI2ZT"F=O5D[4#H-
<1Q]I>U6S:U)U6G4O+H1U5T8TM'W'\$1]U&J* MU,<+&8<.,)S9EBCU7Z\$UFS='12M*-&*TF'-
T@P=&0,LCMK3UGJ]UWS=(CQ- M'&)-UVS;20K-U!74UXB=V(K-(H%KK+@AV) JV_SM(M=V99JV4?FSR(#&Y'=
MV?'9\$QUJ]#2+V:1=VJ;J)UHM&H&-U# '1AX&QSJ<=V[(JVVNBHF2SJO-TBX! M33V!J[3J\ =W&C2V#QMBH21VW?
=\$L3MK#Z1U,+JW- =W5%2W"8%%YZMSJC+ MW\$8APM+=W=[_=U.M;N)7(C<:/:3@G=[JO=[P9MM(N,4G<=UKR]
[T7= V M/5#477-16-X9>] _^ _\ _DN.O'.P*M H'. (GN * D@_O9P%SM^VNN 2/N\$4 M_DCBS7@K >T6N\$GDDSC<J].
&WJ8?N(HGN+E9-LMH>\$9JN(P'N,R M3EEUVN(E;IPW\$3PSON,WN,'#'\NP=Q,88^7N1&?N2D+=\1Q7-(WN1._N1H
MW=GI9\$907N56?N6=5_N4P5==@/N9D7N; /;YFGN9JON;>7;QL M_N9P'N>Q3=ER7N=V?N=V;-
XON=>WN<.%K5^'NB'/N@-U)'?%?NB(_Y[H%M32 MBM[HCO[HR1.DD#][IE%ID9.KEI[IFK]IG-[IGO[IH!JHC[J]I%JIG[J]
J MJK[J]K-JE"5"KA[KLC(K-18),M'[KN][K*A)]%NM[KOO[K#0)8P#][LQ%LS0(C MQI[LRK[L2BLJ\$[LT!
[MOE\$YTE[MUG]MI5%RV+[MW_[M1@\$] MY'[NZ][N9Q%"ZM[N][O[N5%'#\#[O]-[N<6L]>%30^K[ORPYJF/8IQL3O C_P
MM^YIG39R%47P"K PJF[PE/9D6L7P\$C_QIN[O3\$=<%)_Q&D P%;;Q'O_Q[UYJ M(# R). MO%?
R*) RS"ZO.Q82_N[PH;:R,O\ _PG3&G:T;X8-R^ _\SH?9C3_M/T /*+8^/N#W,CQ_]#V/]\$H?
=4'?]\$Z_ZPXS0BP/ZRBY]%;?)%A_J9V/]\$S? M]?TA["(Y)3]BUEE?JEIO]FC_%Z _JFQO'<&5\$P8?&-ZXVV=?JVE_JW;/:6V_
M]WQ/&[D#\$WEOSS#AC39_U7A_ ^(&?^(AOM7W?^(XO)?1B]G)<;80_ (&2L^:K/^:R_ ^*#_ ^K /%KBS,Jk[HUN?
BE/_%T].VU#U&-% [L#_-0TO[PW_WR M'_T/_V _C[7?Z]ZS[#W?_#[ODD @4O@0((%#1Y\$F%#A0H8-'3Z\$./!'A(D5
M*5ZTF!'C1HT=.7[T&!+DR(D139Y\$F5+E2H8\$3KB\$^5)F3]HS;=;\$>5-G3IX[M??'8\$*/E4*)%C1Y%FE3IR9]-
@SYU&A7J]5*E5J5ZUFA7K5JU=N7[U&A;L6+\$G MEIY%FU;M6K9MW;Z%Z[8L6;HZX]
[%BZONKUE1\ _X%'%CP8,*%#1]&')CD8I&- M,2:&O)+Q9,>5*5^V?'RYK9V?>MRUGT:-
()09 _G[KU:M6M6;J]V1OV _O2 MM6W?QIU[6S964#YAT\JF_BQ8T?1YY<^4#S3,OCYS9^73IU4EJAIY=8&_A
MM+5_!]=?QY/7GP[=V_AR]PO?J<\5'Q\ 7_G[^?W _\2Z 2\; MC2S"J\$-P0 4)!-"X !X\$JD\$)!8.P0OHLQ!"#3/DL*
<)/P0QQ*(Z?!\$C?< M2D055V2QJ=C=P6A'BDP[C]T8;\$!0Q(Q=S0!""7)/SLT=W MC1/2RO%)%(.)^6T4Z,TEP76*UV')?
97[^)#(=@IB66VV3^G0HI669N=M5II#W46+V.I MS+; ;J5%EQQ->RV7\$#[':ZU]%ZYU_GJMV F!PX+P(" _-
+AAAX]#3=Y[[W67HM;?7BWA6 *_J-/T889)\$Y M[KAD"4/NRL21QS*Y99<1.TVIB?
&M>&;JWYJ63%S;GGME#VS6>AA_X.Z%Q; M7/DGHI=F&BF&D[IYXF[_+Z9ZN@NNGJB]JYM>B6>NOX[(:*K
)KMLR,2NZDI> MS6[:;81*7*KJ6< \]H=*;2KUUYUYN%ZS* M+S97\N8PYQSWSG7/'&^]?6]]X31??
WAU#XE' G3C^TR^>>?7)%5VVVF^>;;\ M*L2;(MXSWS[WWW?W/7SQ\TY]X>?=7;Z^PL,/7VSUG?(_9K@I[_DX-%:W;]
M-X,[+BZSYUX O3= \F.;^#8 +%ASK1V6]8K.) Y4"P3:ECH)"D2!ADI:H M_X)M,#BD 9A:IE)! M'J;K:SA\GPX-TT/5.
(N(QRK0MM@RPJ]K)!7*#X9SV!,A"*F[/@#+\$8A:UN+7& M^4J(CP*B_8XXQORX+
(Q?/!L98<6I]JDQ7K8QUO686+F\]"Q59SB"L7WPBWV MT8]8.*ZT&BG,UK0C8>44KX*.4C^(9)E='+D&ZO70"CJCFX
*6)N]!C*_ [1 MDY]\$9>\$R4CH7=!P0(SD)BU2%("I6L U(J\$Z8;T'T&DK?4R+LX64!0]M*7 MO73;%O9)%8R39;#-D-
D1D3E*W7/LVH3:>\$IF&O@GAJ29X_3R]4MN=M.;
MY#.,J(9Y,&CF4&CEI";0_E1,C[EI<>ARG[@Z93D>%\$WN,1G+G7Y37[VTX]D
M\$^Y#0EO#P(R9)&\$#BV9SFQS%:4Z7J]F0KFBDL&LI M!W]F4MBXZ*?
[01M+B4J3S2S5I>Z9:7QJ>M&2[#.G5_6GT'C:TX5"L%Q!C29\
M8.I4\$1W5/L9KJ%.9ZD2P#N]LX0+05&UZ4ZS6M9LO4Q9759K28:E5HE52Z_WX M*MA4\$M*OYE3+6%'93OR!2*_5(U
<11+,+C8U;*_+E6]0H@LSZKK:@ZJ'Z M"Q* NJP+SG*:2<\$UQ8]UJ*<>2);+CM;+2X@? [+ZV89ZU5E.O1=@WW/(:-;
M3DZ=UJT/46V(6+LDUT(6.X*)4UQH.UO;BJ^ZX;-MP2ZEV]TBLU-++=DR28O. MKGJWMVH=7D\$FB\,6K3=V6&KN:
[6UIQ-.JY07]1U^Z;?J _&7I(WE+E+)&ZB8 MD@ZA.AWPKA)LJ]:6=\$G+I9-S;99"/&I-7T@]C'VWR-\(<-C#X_MP9+,%X [M:
<%UHB;8CJD=X4+UQ_0R+F\N]U'23A&%-YD"Y^KE@YQ1L/[!7&0K2MD![!9 M>'VU_U2)!0S<,KW2;>F;Z(N[ZI\YQ?
B(:4VRJ>)[MSQV6<>?N>B)/3\$!=Y MR&WI:N MGRSSF&L:#4#>=&;C07)W6I]+[9Q7&>
<9J;MCP[8UI=GM:NE=_T71H[*VJ]! M1G67.^G(C,(PT9)F=*QA/>O^&IG6'8;T=0D,+N\$;&-0_\$G6P]^Q,!VEZR0KM
MF;""U9>N\LZ.;RH*-MV59^&M>/KC6VKVWM5V=[V]<-%Z3KE-M>7QK96%+V ML-
J.G*TN#WN+NBZNP/49A>,RQI)]9,C[[/;VY:UM _#O!;A]O;[OJ]V MKL%I)H;:S28;N?=6 M77)OZO+?3R:XOCK-
=ZKF\,YXS7G>=B)3MF?"WVX.6 :V\$EF ML(,W#(]+9S16H;,7Z:I97.BQ=WR_2Y->MP2=:KKW? \WSO@_SYZT05]ZTA>?
^,?W^W]0GWK5 MTQZEKH=^ZXLM^*;UV?1;TVE=;7\K^W>\H>);643+OR6(J _QD? _^;..:S
MO_I4SA+V;1_V[#2^_H_WN/S-PV#*L\W[<2\A^A@,\DN_E0_T3_TL.YW'. M!30\5NL!F0X_&N^!S0Z_3.A\
(3Q_F_DB_,X1"-!!3! R3!\$<2ZN8LJ"60_MZXN_%%!)&_** ,^5)D_83*MP>/ #M0P=S'!O3!'D0_X]@X.-&%WR_UJ
M"#1"D: +H)O!XJ!K_\$3&QP='=Q![05*4Q?O[1!FD10CTJQ&QQ1)
MQ2)Y'E24(:A,M')IQ63D0DR*Q5O\$LUURL\$HHKF[1YH#W410L\$NU]<"D/DPWU9 M'U0T1FX#,61T164P+L '&?'0VM*
(XSF8@Q%4'LM%U<\$>-B1O3:.E-TGI(+ MQX\$+1[HQQW),/[G8&'4LKTZD-^FS%0\$\$(W94#GFL0+)*C :KQ _X^D9^ZD>
[M\$]>[&Y_2*"K ",B0_#N"U\$>#]\$1Z+!8,A E*E!'N,RQH?\$B'#\$1NO\$-M)"Q[MNL@-6SF4X\F,9+F>9+,[\$0_ \$B1-
#VW8\$3W"N4'#U\$=,H+:4<67\$>8M*;/_ M4@Y[7\$H\A!^_Y.J]-\$I_W\$F#FY&A% RC+,3YL?:F
M1\$&C,@/^O\$F&VD>@[J]P[N-9+3/*PP05!2SK\$TK""U\$2J]=:W=\$NA\BF9 M1_ZVY R*\$S\$J)Y"R1V4J _\$K
]P" _+Q:BXQ,M(VBA\$22#%_%C\$;)=)?=\$SK M"1"*MC#&%JP>C#&G\$MP.1^>[R?>+/_T'R_X)RZHR06PQ3!M_
JU<0RNMPI MUW1.:BPKUIP^YDPBN[02K/2/#1K&S^3-P_P^X?S.OJNUOF,6XS0_Q"0VY5PG_MZ>R9UW3-U:3-
Z93+Z@RJ4@E&49Q%=D>GP1/T S/X0/"C3-\NP4%'/3I%- M%7//8>NS^Q)-

ZAP,W(0Q"96G9\$!\$C03.#/6[1S0#BO.#E5 Y,RD SV5! VD M!1VC56)/XC!1I-@S@XDQ [A/2DL=#?
5/#ITY\$#6^#S5/\$4/*TR#19FE1YT%1 M8+KUG-%UW15UW6UH04-\$6D]RTL]07:EUWJU UW0% MU\\)4^@DCG"E0RS-
UX 5V(\$EV(*MO7TU4+?P5RTTV(9UV(>%V(CMU/AB'='- M6]@\$E-B,U=B-Y=B.54N\$#:NV@-]=F?;!5KX2;><='F1#-
JC1=JD5=JE'1WV(MJ79=JH ME=JII=JJ]9MT?%II]1(?LMJN]=JO!=NP!38:N0MX'5=)=\$=NT5=NU9=NVE=5*
M#8R8<=NYI=NZM=N[M1-"18P]#2*)=N !=S % =S^H-/!=S#1=S\$55P!-X27>XC7>DPV\
MXU7'DP7>Y67>YG7>YX7>Z7>Z7>ZK7>Z7>[-7>[O7>[P7?!(727?C7? M\T7?]?7?]?67?]?G7?]?X7?^)?7?
^1U;@!&#.#@;A\$!;A M^+6,\$3;A\$T;A[6,%&;A%G;AYJV.%Y;A&;9AVYV.&L;A'-9ASU60'?;A'P9B
MP\61(",B(C;BM+61(U;B)6;BHQ63)H;B*)9BD^62*;;B*)9B@<68+.;B+O;B
M; *65+Q;C,29C5IV6 S) &XS168S^5FC5VXS>&8V=LXSBFXSJV8*;ESO6XSWF MXYZ*FCX&Y\$ 69/LAH4\$VY\$-
&Y,]IHD1FY\$9VY*:1FT>6Y\$FF9%PDG#NRFTK6 MY\$Wfy-XC.S"1G\$X6Y5\$F9?
2D.U"^(I5)6Y55F99:H5KRXI%:6Y5FFY4+D#<"8 MHUK6Y5U6Y5>^B[GBY6 69DJN.,&0KV%&YF1.9%M%96!6YF>&9D-
6E,6WVYF _9FZV7W FYW]69G&N*G-6YW6F970>9W:&YWCN9'=.
M9WfVYWMN9'I^9WSFYW[F8WWNWRT%"W\FZ()F8(#NDA_ E4X-FZ(;NUH!&E?M
MTQ%3'A>'MNB+YE0"CFB\$AFBVD!^,!NF05L<%/A6) @BX<#"15NF5MC20V&B3
MUB>!IE"6INF:MI\,/A6.YHBXL#V;JNF?1IT/A6=)FD1?4J@1NJ DAN3)*&FB MUFB4?DZEENJI-A@&*1687HR[H-
A\$!>JN]NI2<0Y7XHG1<&H)YFF6Y>JO5NNU
MMI(;DP#412L;HSYVnk%68^N[QFL)Z>&X90W#D&NAIE:T'IN\)'NS"UHX\$"0Q?
M)LJ_ GFMB%6S),^S(EFP%'N*8+W59NVSJ&+ +[FO\$,&W'X.O4]KG6QNW;NNZ:8H;YNJUZM
M(NWN\I.J.:4):.N%0\\W9OELyC\&YNIE83M9M8Z,9O#-M?N#R?@2;H/]:R M^7Z.0)\$X1]7N U>C]#72-
/614GY=7/1T&D6<:EEW[Q]8XW)U-'(I?R(B=>'5].M%IE?+(5 M'Q^0#5?2<9KR,*?RWC6: ^O\(\C7.)T/ER-LFW47?[(1S)]6-
] % ?<]7]]GKQ4FN*9CYH!|B]"YG"1//5&7]5%- MW8]6&'>49+D*0),D=3UW=;*A=,*;]6"SQN75\$Y44T9^K*T5LQKQ=
<0>TZ2Z M.4"G=CD770<%(?I[9-=*[*\ (M]P41)3;MM6JW=R4\$7>:-CW7_XNTVB BT3;M= C N(=POYG#7L-7-
7^"L+W3,? M(O)MQ^)I+@J)ABXDDNV"WVO#8?AZ7 B.7YF&=_TPG4KCFZB _A=3Q'FQOAP M/W@+3?
A[A _E!S >0AY21;V*IB!;3;I9GOY/09F;\ _B@IT+-=?C:M/0E3G23 MAVE36 _E?=QR7+S>AE _J%]MRB5W6:-&+
(+@JB9GJ>%VWET<[4B_FQU\V9QW;; M %8?9N:Y _J=;WJ#/_YV5:D'RI _N/VURK%WE)S _I/9ON SA:O[WG4\$9@OG/K"
M+P^0/WL>P?<@]@R9R>R ? _N,IZ\$CW\2ZMWP+0?POM<1QW_O8SGG3AGS _WK! _M_W@/_O?S3GXO,G\&?"
8BOFRD4&_*B7RX9?*"CEJ\OWG_FJ]*D)Z7H?Y]Y19 MT4]B0RI[I<5])C[^W\!:)4]/SX_]BIE]R8_[XC _Y&= ^W?.EX1B]7]M
2^7 MZ+ ^&A";^0%=:ZS]B] >.'N%B["Q\$&"B0X,)!A -Q,6SH""\$B![(G4]QH\2+&C!HWNWKS\WKMJR]"MH)Q _XM#-
@PXL.*\$]U2->@P<&2]W];QGN9IOA MUXOWFOX] /CRYI.GR=ZWTN;ZE_/76W]]?P'N-R]U>\$57X(\$1_=?=>UQM2"\$
M\$?;4((4.KB0AAAEJN&%2%7IH(4DJ]]&/@J)(9 J&KGBD\$GB="23#RHY7Y%1QO8DE55:>25N
M33JX%/^-7=;H%V=!4N4EF1\CAIFI3>>!"F/98*%E _@LJ:E:BK+
(Z8):.J@K5/E^E:TU8XU]!Q6;M;MMAZ*]*V37WK9[@;=GLN M:-NBNZY;F[\$KVE+&+NIEJ^=6):]B: ^J]:)K-/OLOP
N5*^Z[F0U\| %+CHHJP M:04[K/!6#,\ \$L:,2\$ _DPQC"QFC"2+K9L5&^SHLO@62M.R/_ R8#MFRS+_SH; M<,
6IT0Q4C+;/#(>]Z,5LXJTQS4S]YK&?0" _\!J='GQSFT\$,U-3+4+8JU M-,IEKEPIUI?V"S/771==D](H?3VVT&\$?
2:;T3:MMMM-%LWTVVO2MC2Z?XBL>=MXJ.]10XY)7K*K'EGTI^
M:N9Y8DDYKZ99#FG??"]G5;9K[85LUOP2 _C+BL\CE_FXG[(!K_.0PVMY&O!5FUXZ<561*EESK[>>K.&S: ^]U\1&]W;W-
RH]' _M_D7B'W]^Q+::GR[Y]*%M(GO_XE: _-C/7] _J%R*0?@>XL\,/?Z<*""J48R' _7 M.^&S8#? %7(-
@;>KH+4N6*KVR;"&DP)H6PX&QBZ3X=3BI/_QY<:R'D.A! ^\$ M4;7^9T(6,K&)B2,?XW@8K2'^I'LWO"
(5(WBG+%Y(BCW\$(HCJ\|UL,9W@C\$B M&H]CKJ6R,7M.:?./L:&@W+[*BRRIW1CS:>@/86F/8HN/JPKEQZY]<9!\$:8T9
M)Y/&1>YE6X2#(R0C]2GP19&H.#*DMM"FTQTUB\$BA5ZJ1[QB4G3O.*)T42FWR MQK[C,G(QUO]2H@I5*\$E9RHZ28;-
DTDC9M]J+ILI>G;\$F20 E(M5WIEU6TCB _A M99L.>H:5S@QAM3)%RVE24V"X,QLN<*1=W/,9J\$*%;%TFI.?
JY*5/T,TS,PE*: S7\$T _W@; M5;+FG0Y53#SI*5%)U@Z; ^-RB03TFO(QRU)PBTf=ZQ)>|CAZ3>0EM'#K99IM6
M/A1,:YPH3.OIN+E=%*.&!/A)3WI*#8\$4/1 44DXOYRZ=SJF2MV\$14NT2KI@R ME8F.NV5-V]336.DTJ-Z4T%3-(T,?
6;6+@JFJ1K.DTMTDM:P"B6C_4].Z;/19 M-*16RBjGN@JGM2*P"JN]#+JG=B>(0/6KR8C:'-R1[
MK/9LH9VM+Y]G^5=MHG45;JKI5LAFKKT]2.SIIGMY]V*V% _^JN=)7:XS_6C(\KT'!:M;4WA2T5E23=I;AVN5"%
MCW632ILP%DN[]H66Q=[KW;TRET^1->XOSU/Z^&7:
M_*!R7_OFU[3])>JYZW;20G%4] _TU+S^K [3>WBDW;EEL(-3C!]?*C"HJ\$]8N MPRQ]81,->\$B.I:!\YIA" ^98Q
G>R('1.S0,-5B^?667BU\|6IP*=|8EJO&) MZAJN'E\RD4=)(!OC)\$?"YEB&BKR== \$RK20KV;_7+ "31V1E@%Z58>"M\H<5
M _8VC1@B01:C?C,\$9J1Ff\$, *G-AP]7D-'TSN4L[I]U"?78=MFY=ZHS+J K MH>Z*.;JAMLJWK +H0\$|1S83>T)K-94S\$M
ML&Q.K=&21;=:;G>I@DG2FI=9-J(MZ\$='L"(QO6)5*SL4N%8V2I]407L"G5 M'BW7Q]XUACN*Q _L'AO;_O9V/E==X
P_.DG+G=@H#+FLT [IM1NFKY5.NP2 MY;1XOU[HO7':.%,5>];T+K>2T/W9Z\$1W5FQI=Q.E_2R%:VH!<:UVO"\&;C7W
M&GS5"KF&91SC>&8,OI!D#X0HPM]Y2RG3[GJVT&7IPV M4';9K'>>N MYK77^=1SOOR9=[5#7>X8@CD#',W
MWWK/KG3W0(=%.'V'Y0E[:_99]M'IC^&NY8\$X=1[>FX.I X[CK85Y;|5|X(2 M^>=1Z/>M\$22[:3W\PA\$O_.
3WYI=3_OI&_JZH\V^ ^78?(4)C#_OEQ]#Y]JK[MD&-5Y-Q;[Y'&C];H:4DED"1B.TIH(!-H)=(_2R(')H/MUV_F130LV
M2*B<(*N,3/?EGZ;(4A/YWO;XWP_*8 \$&H!\$_R_QP2%F\$2+EV4+1X*UMRI%5H- MNN 4[M]IP-
_Dj:#,4"\$%O=O/(\$S8]1T/>F D>\$ (N_2%E[AL1GR:'Y12&' M5*\$7RB\$WH086MM\, ^MH<"E6LX&_T_44'ZAX9NI&[B6#
"&\$1#J\$1*J(BI]C M*B\$DEN"DY9D;+J _T=@>TN\$#NEX>EL<=GIDFULRV:&'X^~P8"]++I)49MMLC M&J
KJJ\$!BIJG52*(P:&&9"(NJA\,=J*^V6+QS.'!D&*Y-,8I?J /+IFU(. (K M,F(B-N,KMB(L1B,T3N.TK9T?TB*!6*\$Y"
(W]MLN^J(G;J\$FA*:F9[\$B"\$9 M#B+O;9,S1O _B&D+(B6%CL9@ (76C/O;3-U9@+?IC]X3B"XZB.5H,
M*AKC&2*.MW+,CIC-#)C/\$:D-,HC/\$ZDM%VD&CK6ID9.EUP:IL9IH^!)IFNN&AZ"8R]"93V
M9.\$%68B#EUM)DTBCDV&YE8F(6D>IVF294&JID>RIC6^)G1*61:6I6V<9--%
MIW8\(\$O63F].4UI0C8OY)6B.)S4BIWF;GIZ!W4QIW+*YN-AIVTB9FS29GO2
M)|+\$YPI%2CWR3G>2GEG0C:9U)GD6)X&>IX&BYVE2(\VPYV'Z6P'")X3VTOM! M9G52]#9%J
WZ5V[&37_ZY[6DCE@.*" ^Y8&6*(F)V\<\$(-8EM2W\$ZM*.XY M9W.ZYZUA*/S47FKR9X="\$N
AC _VJ[@_J(D.Z8E*_YMNO!",WJ.,/N?)2DF M4F:D4]I3@1]7]BFG;JJM?F6,?&JISMVIOF&O[JH,BJJ;RF<&/FK'
M1.J&UBFLL"TU*JSWNJ?DN2@_BNOIFI8DBJUBMB\$=+2NS
MVHH!/BNZ0BNN=@8Y96NU;O^&KQ&&KNQ+FFWX;O.K*V^90RZ!89V,Z;NY^4|'U;,N%K5O!
[D,2H;1+NW*FMKB+MNB M+E?I8M_0CZ1I[]QJ[WE](E- FK8B;50I[Q.%BO-JKAJ.7?1*[_3J;L36().E MB)P
K^ATZX1VK52P[N.RTW!1JC(^9*R<;|U&1>>P\|. "KA5(;QZ9R;N4Y M,& ^
[UAX+TCB[&F1[[],9ZV<,765/C]+PVS*Z+06@>CZP>O9PB'K.*\$RFN&*ZVT_ZK[MB_5^FH+LQ@% MVROR)B\&3]+-
&@D.HR_- [K" ^JK])VN]EB20,+ZB0T"]5IG;J2"/NO'#0|O#K M3A@- R!\$ O!O[@]8Y+#+
!MT58W\$6BW&,YBMP".X(4^P,W\$1WZ_Q;R//,MTQ&S M_*K%.3]M.B/-J=N-8?/,S_SY-*S-
1^T+8Y[SZ]S6*!/AJB.'OS58)S7Q(H M7N*!B,7,2.H%8-G0;?=-,=E0NNQU.%Q_*T1R/N0B=Q/O\.-^ H<'TH(0T
MP3Z%P95TW9YTC:9T?)JT/#]P47^G1+,PJY7' ^T71K?Q4YLRD%*C >GT8/*T MG/KT3Q\UPKPSA!KT+!MQ6\, _F:(Z,ZT
WG7Z-UT*X**56,D_8.H5KU M4"]F3(\URM8U59PUOB(-KON^\$IU1HNS8;U1^_I_19*0/MI7/OH7-,U5P?- M7:??

M?" =4MCJD OJ?OBLPB#|[->%V)/-4[?R5N_@-'=CPS-.JXJ2]+|V03
M_FM :%GO;FUOK Q<|#:VG'26,?)VI3B&H+L5Y3766[W5]S M|B;WL6"IM@GC+7=<41K'U&@K=F@62D@W6X4D]Y-
I<6LWM|>%KDO;<'HC&'6C MW6TODP(-F)O-&G7JZP"]XDRMB/G+JR(JWBOMQ6Y)N@DL&:K=X'[Q]!(O+DQ'
M]S8GK23]-FD'=Y%Z=S=W'7[F;B']_7E[|D8"#3!UM>!@?.(HD=7B1N"__E,(? MH6^O>#Q*N+,22H5W[&:'1H8?
[FP36H=#=K6 L8"-H* M^SQ_Q4PCQ\$N)%HH 3T4IU;B-.S0VFC?V(C2 BPJ(>X1?NTU[-RZ1>Q&+<[>0WO?
MPCCM#G<C:4H[>(6QN5HY1;7KD2R[G7=KG,%?)MZUI#%'GF8]ZF2-RV,GS-X M+^2:% I^!;&A)[JB/PXI55"?
W^1;SZ.@4+&3.|FB7WK\$C1JF;SJGXXZ\$%I"8 M_[:+QSB:6PGZJB_I=KJJ&V9/KJ]KO[HE03?9/JD&W=.-> "@GQ.L[SJO]
[JO M_I&I1= (GFMHZW>I6M?XQ"P+SNS-[NS/[MM2_?7^#FIF^V@Z+#Z0KNV;SNW M=[NW-Z@_*0YQ%CLR!|JS?
CNZI[NZK_|[NRMW,Q<-N? MH*!SN]>[O=|[ON=[M0R^W]E5[8Y|P1||_/XD|3[BR<|.TW&(R.|Q\$||Q5>|Q=^M
MIB|5PPN[4+?P77JQ8>|R(|R5,|*(>*O||NIOWS6FAJR;||S,>|S*N[G5_)
MQD=|I<|DEX;IS/>|S_||T,ZGM_ZS;M|SI,16YQGT"|]TS>]TV>XJ]=|RLN[M;,>D|0)/FTV>]UF|]JUQNP @_)U".
[|&C.8(ATUY|]VJ>]V@/K|9)(V&|LP#>% MFF|&]3^+U@A2]>5[[5>N]X|^X1?^IX4D>OB]V9N[A1N^XS|^ MY\$=^K,-
S;KS_/7ONF?/NIS.NA_-%0H M DZF/NS'ONS/OD_G>!=*F.MG/NWO/N_WON_GK.WO4.N/_M__OO\$?/_(G_YJN
MOK+C/O\$OOO)'O_1//_4K(|,#B-]7O_9O/_=WOY.Y]E1DO_>||_F7O_F_G25C
M__OFWO_N/_S'S5N&_K#8OS?/[GO_['KVNJ]?['O/T#@\$CB08\$&#!Q\$F
M5+B084_#R#&E#B18D6+%S%FU+B18T>/'T&#&#F29\$F3)U&F5+F294N7+V'& ME#F39DV;-W'FU+F39|^6!\$X
%1J4ZM"C19\$>59J4Z5*G3:\$^E1J5_ ^K0E@LB M8-6:E>M6KUW!A4;%JQ/LV?1IE6[EFU;MV_AQI4[EVY=NW?
QYM6[EV]?OW! M|Q8|F&15PU,1'U:1)U> ^G'ESYR9K MTY8>G7I3R+JQ[|:|G'MW|] !AQ<_GGQY^?1IU=?
OGK[Z>^5NLP^7WO9]??Q MY]>_GW|_!|##_0E<["X#W9QJJOKHHX^F|P],4,()*:S0P@LQS%###3D<
M+T\$\$.N.P1|WB^E#H3I,4<4566S1Q1=AC/]1QAE7/!\$^4C,|2L3032*QA^! M#%+((8DLTL@CD4S2K -
=TM')RV"R|2@EJ:S2RBNQS%+++;GLDLH&G|Q*)BF1 M|M+,,|],4|TUV6S3S3?U E-.KAXDDP
X|W4TX,DK>_344DMU=1344U5U4T" MK6S55V&-5=99.:W55@M#G>S677GMU==?
@0U6V,%RC6S88Y%-5MEEF6W6V89: MW>K9::FMUMIKL>_-'MTE)]>W_U|]_0Y88'>=-'
C@@@Q%.6.&%7|V1X82122[9Y.%V.UGEE5ENV>67Z>[9YY^!7GFLH(DNVNBCD?YWQZ29;MKIIZ%^UJNHJ:
[:Z]NQ+E7,K+GNVNNO MP0Y;[+)'>MOLL]%.6^VUV6[,:]?ACEONN>FNV^Z[|_<||]!#UWTT4DOW?33
M44]=]=59;]WUUV&/7?;9:._=]MMQK_""W+OW???@<|O]VZ#+][XXY%_VYW MWI-OWOGGH0=M^0B8C]
[ZZ['/7][E=]>^^^!#W|FZH?O7OSST4]??8RX'W|] M]^&/_X+R+*???[GQSU]_Z-MO?_1A W)6/@-43X_1F\$#2]<|_"G3@
R%H MN>E-T'T1M.%4@X|O8O@QWTX ?K5C|13A"%'33A">V00:BD(4M=.'3[?%? M\$;Z0AC6T(U|T9!
W&4I1CO(YEKPDM*5&92E7ZYI./##(!5QE+6^Z3GY*4IR7|&5"!|C&?W(3C0!&:T#3^\$Z_*=>A#][A._H2HA6U
M:!:9:DA\$7I2C'76A1\$%:4AZE*0EO6!&36E2E:[T@1,-J3Y9&E.9ZJ]^0*#WE M3'&:T|0-X 0]!8I/>QK_%)^X5*2?
U.E1D=HWH"Z5*\$P%R@!R8E-;|I6J596; M4X/ZTZ9N]=7B7H_JXZ5K&/#ZEFYFM430)4F4IUJ6>\$:_UZRE%:U:M:M:
MVQI6O7Y1KGWU:]N6E>UUG4F;GWK7Q&;6)|)EK%TE4E1P?K2Y2F6LI6=&5TQ M&|C,GB FABVF94\$;6I,-=K.-U6I,
(+M7HXJ6M:W-6&EAJUF@=-:SAW7M;7&[M,-.25K8]?6QD4RO9W Z7N +K[6Z=NLS:FG*CQ77N<^D56]Y.=WS
M:Y+H9M= M[:;+I|>5+F>5NUS;;I>|Y7T6][K=7=Z9[5J^+]++'SQF][G M_WGW3CJ1['_9JU|/#_B'|JTF@1&_M.,
<|]O&K:|SD;OZ8R\$4NU8YY;&0E+QE20D8Q<)>D<92DK"LGRG/*5L;PG)]?X MEUGVI?55&4KIX2_|VN4,&
<9C4;9|MM|J)*SEQF],IVS76.L%BY(^8QH|3, MQJ]*|OJ&\$=TP9Z!_3F=9TJEFM:EQ_.M:] MKF@42?WD1
=W);DV|J|1O6NT2MK7S;9G)PW=G%K_\$]7'5K:NL>UG5SN;V^)| M8K'"^6Q%P_G:ULYVLL_=;75'\$XO=F;:MH8-
N<|];WO5N[+;7G>]SPC%.28#WV|3_?CJ M*6YPBQ>F.SWJ7/=Z;ZD> M|ATV-
J,+AWB|NQ[TM\$]=VV+=SL+4^SNK'<|I"Y1^]9?G>:OYWO&'SEWQJ< MDT[WQ.S4;@G>UYXXQ&.V[XU7((-
QHFK SIWRUW6)XO6>=|T3W/&=UY_+ZT3R MJ|; ^|";9_
(SCWET>Y[UZ@MK35Q=;IQ4WN.1#3S:47_ZU.>>L*WWO?;:IW3A MSX3M]25]DN&|>^7KGOF[1OCOH7|87|)
[[RU<]4Z,? N I MG>QVS[OQCP_ZPW>_>S_/E'\$W_:E1HFI|=^[?\$/TOJ_W_ON=[|?|!U#HGA
M"+#^,@_JTN^ ^S(_VJ_)#7C_2T?(M_J_KZBO|/4HJ0!9_!/"S4\$ " M11|T_U|J_T_)Q*0H6+_" Q[P UN0*)YO!&4P>B#?
T0\$"5Q\$'F1;,*X_8P M\$P|J+JY0\$B-Q\$2LQ%/(LQRN\$9EP+SZQ\$U.1J4)0%VQ:|["OWS11"]7),U3Q
M%O]PMEYQ%ZD&|(S.%U6N%\$T1^3P#G'\$1\$V^0%Y61;:#OJO^49Q;:LJ6|1J#AOQL2AB'4?
U4PQBK,1QU#1O),6=HT1F5YQRC4?^0QQ7L>+*,1YA MYOKH\$1@9CAN[40&%XQC?4>2\$-^&Y.[@21VO3AVA
M<8:0@]J*\$LA_-C%DLDB SLB(%DB/Y#W?"T45>,)Q<#|! S<;R0PR,K,EDTLB,W
M|B5=,B;%L15A|R8S1""Q20_!JY0B4B>QZSED4B7|2UAB3RB#B\$B9;,BF-|MI:
M1RD/TC^0\$LV4"1\$|L1X+Z.A_|B13ZCN",BI?4EB4TBN="=S6L2>!:;#S:T@W_?T4MEW(O);(OS?
+B2.T4P'Q,R),O(S.M0J_!DS%5 M!11\$ SE4YB(G1+J|S'^4U2(4.I^1%G4/S<.0\$24U"%"(DUT1&13XW#30NG4\$(.O
M2(W4|J\$3:6+5-[T3ZL43:M4<0/5_ %C4*0D]X[4E.322Z&30@_5T#Y%4"F5 M3Q\$U1!/'4HJ-
"IU".7TW<(C3_5T0BZUSSPE4C4U55%U+P^G5)>J-)K45?MT MDB!R|]7"5\$?/46&4WRA\$5D%14U355SM56-
O2<(+5Y#YC5>=MDO_LM\$*;J3;3 M0DAK0E2/=*\$&-0PU)4F)55FO]5A#5X(@EIBUIY M]2IODT+_+O)2+V_%F
A=5LO)611=F%|JOL_|V0YHV|UEKH6:6.'3!&9C|8T M]ESM1T6(U5)R%F>#-FJ=[F|4=C.T]6D!4Y&.KR8:4&9G5A|YI&D?
96>AMFS) M5N_|9F0U0VH|][6'GB&@UD/J|[[?@MF|_FZE%NO51S!9K^99MK5&IRE8SSE;> M%FEEZU1"G77E>
3S"NMK:78F-550]]9O*7=R9W5O=A8S^M93\$|EN6XD+Y[9Q MDW9+7>1:'65S!|=R4S>V^\$9G-7=U!T]KTV|,NK9Q'?
=Q(1=0'05V4;=W5=

?=W?W=O@G9XIY=U%TFD@7-|S);?4GCM;XF=-N981/ M&25|_?=]4U=OHG8PT'?EF@PYW<)Y7;S_&M|
<9=#V/1|"WB"U1=UV=>"!>-_MO|N(3C2!|Y=C_RN0(7?B>)|L7LF@D@A>E@&@%8@VT6;P9X,%0XLXA(LW3&>UGV
MA@]W3@OI#OUQJ|Q80CW1|ZT?V.XB%F84O/F_-W7B|INTAX36@TNXP;@V4=.0 M?
JT8C(0X2J.7B2GXB/G7A2>7,+@8@7?H(CO"% M%1=GBAU4(>6<\$2[?8B[MX MA8<8;Y08>^6X@VU(4L_X@|T)
[:*T>B"A*]XA,PP1I[|T=,Y),8@|6XD9'UA7;+DOV8
M@C@YB@MY@|J1A(#\$3/66E.=XE^GSD<,X,WCY1VE(/#DB'V.YD[%2/_*%*" MN92=V2A/V76|F8[|WV-<698W+)?
N?9JN7QJN46#1\$R=5I?)697?T9J&'Q\$81]&#WV9PI^@_1N6|/MHMIR-P^XB0_.2L;41.)9\$?G|661MD7*'>=<^
J\$ _CCP*.J'=B*%QNJ!'^99OU%,@>J*!&J7M#XS3 MN3-
^_G!|=2%TM.9.Q.7EV64_FN66KB=SNA")1\$E'):A3NJ+3S8Y1^63ON(5H M=*D)>=R.N:S92Z&K6J?9FJ|&+)\$?
=|F:UFJO_MYJ8[0:2DU5M6|BDL]=M?(| M\$|J;[I(^+HR7X6N\$7NN6]FKI3DT"MM'63GH0_*,LPZPT=JZU+JM-7NM7?
NIH0T]Q,M.-9&S-WMIK_I @R:L M|XBW1R-57^@_) NRB4JV:J|0_JV;7NYZ<=('A1H|%/J/HANUW_2E,7:XS=X
M|JTRPD7NYB|1\$?<:W|TB|2R-(K5NX.YJX&2R:J8UY,YNX5NY&J|(.)5GIAN/ M|MLT=)N=PQ SP1:9J<:)|M=XSO!'
JM#91GR)N.'GP:L&.'\$|D M|O8M/M%WUN^%;S#_YL|MP,T9_]|CD9<-7RSC|W0PO,T/6J+NVF9P^7;N4\$4
M9R)'S9DH|C|+|2BV2B+Q0)%H; MMEL6P)V5Q=L8B!&.:9&ZK<_*/BAY|Y*"<6M>&|U'/SSX'|TE5= MP3T|/6%&TK&K|]
(O|< M5SVPG|9WO=DU6|Z|TV5D?8RF_ ;G#E M_==GDV7,78P2?KB,\$)*_ %A5Q-: @G>
IGM47,COM :O#)0H])=|OJR5)|@K+9 MM2X\$+F;VILK/N7E_9NO.CQ59N%E13@3!>9=JR GEK6;VM1SGMVI/"XDNTF>
M;.55GM?#?35/QN_9<|'-4^07K2N]EO[W-^AS\$#0>R5T?>B%/NOG>46"|]@E

MAN;'^7 5!.Q#RY3[8>C5:5;XL2TONWG?4C\$O63_FOY01)M+YKZR[C+DI7ZB MSN(!/0/K
= MX_SBC9YDR)Y/1)N_JN3P^U>2992:T][L(7W4=9[R>=Z6=P(* MUU@[!3 P+1WNKQ/,-?YT21M"N[RQ#QOR]T.5^W
S26+OS?IBN> O.[V*Q[N M95YD&/,]\$,I^!PYG<7!6(5 ^D#40R0YZ-MS[YP-#KB_F3;/ YM1SW6U-D[GY+
M2I\#9Z3Z%9F1I[(BY\XC]_6MPPG/O\$E/! ZO3T",CW[#SYD=M]*ZOK12Q?X MUJ]/[TP.EV2+W1?VUVYW4+_ R
0*7P(\$\$ "QH\B#!APA,, "3 |X;#APX@0)UJ4 MB+?%B1HH*.WK\B.O"A0@C_TN2/&DR):??
MU;%RX9>?.K8M7;EZZ>I>V_OLX<,>^? O?)7R8K^#%C!L[M5ILX[E]B"=;YO@X[V(4AB)WK@SZR1"?
@F:%)Z! %HKHE4@-^N*ABM+!*1U#N5H
MI896)&E@EB9J:96<7LK56A+2!B&IOI4ZH.FOH3IJJJZV>L%\FRZ:&9NVMGEK MKIE*.JN!N_X*K&:~#KMBL.8J-
!2QO8+Z*+/L'6N>LL[W@EMM?Q)BVV1UE*7 M(.)#\D?IM.V)6:Y78[YI.GIGENN8]TF11JN\N8Z[TEQ-
F=OOB/)N6V2S1+9 M:| ^^^3MOW - *O!|2|LKL\$(|W.8NODNCS#8_3+/'?=U<|V5.!U ^VTWIZ=V'=JBYT*
M^:J1R19JA*I2/OGEER]F[W9F W]>-IMQCD[X=HFG5WKJ0#.NN%&JOIWZZ:(. MCN#KJ;&.N^VZ=S1[!:]W3ON3IT8?&
<#,,;UU\IKI37SYH;=+7F@3T_BO6F/M?GWV(^TN;%Y<@^?+1" YTWON.OO SELI|^DZSS [YZFND]/B|\$^ ^:8ZA
MS' _LEP(XK?P8<(9P0AO:\$*BV'.+P31Y< M"P9=U|. @MN6'2Q(B6TY(0B(J.8..7"*GC*BZ)(.09E*,8(LL"))]:>Y5EN-B
MY:Z8.?|OAM\$U."P4?PB(QC99[X:.TZ&)H%@5).H%CG2TBAS_5<>K5!&+=W2B M18X'OSYB+
(^\$VZ/0*@9"0?:MBH8.2W1:N#P62M*%Z)+5T%"4OK*MT8UL["OG
MW<@O0BI)D1<12GMU\$AEG1(JJ>2C* UX@OBUT^KG!LLI :P5\8N;Z1DRG3^
M!|Q@E.SB2R.C6B(SZ%)OML(UOK.5.G.C.:"JDE^*2YC.IB4U=|C)|V9R2->MW M2 +U2YOO.R\$Y.3(V2D92G9!LYV^F\$RXO
C)E:S7I?I27R"LXD9&B/5.XSV9B=|.M0C%G7(2L)IT6IE"!FVA.6SH[W=WT6\8:EQ%WJIAJ
MX719.!HI1+JSSJ2ZDYV3M(T0DOFBD^8SI9^4TSZMVK:9(F2)\|0J(6VZ'J^" M=:Q&:=SKR-J>8WGK@4
JE+*VJRNH@BAY1&F7>^*.B-"M:1NHJH^L>?5@G0S ML*)L:^U>6E.XHA6B.2V=81-T+.&%3/!&#W-5C?70C6
Z0J9Q5:E-5:\$2^UG"T M5?5KJ|QZ-JR|UJJ\$=4LV6UO^Q0IGL*E|&57-KC:4NFM4|2=;CF4*<;*K/ ME.\8-8II*QWX!DU
'==|B?+;*6 M|L| OJWNM@5L).?W,R7)G3%0." M=- 3B1&D.V9NFYNKW.8B6;I*O&25?M?)P?
VM53VH)GS@N4 "WK.4O:H.." M8PX#|I#?!?|2.;5%|XWU":>8M*^14MDWHA8=#9DQHNJ|-9YVHX%EV%L;^VH5|3+
_5-%V'ZTID>-V[F7*). M&|O.J!VUN|VM55.S6X&Y1B0\$TM:B|U9@P0GPU7YO>^0,V|C'\$QUCMY\$< M4.3|^/
_SFL8D7OFEJYYL(-XG#I|VN+(QKC/XS8"=E=>|/6?13Z/7CMZPLL2]7G\$V7CSLA! UOI==O Q'8IV M:
[SUBGF08+SPMW<<- 7/1@1#>O*6|GU|=^|0.. M*-D3SSVWJ|Q?)S*"<*;>=D)3/..C.X+4| [Z1]-#T-
Y)0TG>:\WV27,>7 MZHT|>-9+7^P!W2|L=2=Y/^<>;L !/F3'27NO-W'X S EZ%D MWV.. TU+K| M/1SE"8(\,|Z?
1|7E"A7 |UO' @|G#=#8GOU.GJ>|W&?9X.D-T-ET/MW/U7H.."T"i40>J#H%6#ZX M9X(1=G|UEX T9H
M:"0|)84Q2#0P>#2/X815F\$6"0FF"(H'+X'%'V9(' MACU"J:(B|DVO9X2%!(+!UT18N#|\$H=(2MW.(7O97U@
M^'Z'>#):A&|T|X-@MX:L9TU%^(:\$@X2Q|X?^ 85T@X57AVV7^&Q4J&5=AH4+ MM(0203?R-BAC*/^&J|A"7'>&T?>
(L4A|T:1-DPB'14=OI5@6D:>+ P:">9AA
MVE:*@*&++B4I|18I.GB#RZB,S=A)V@B*X5=AW|B+;&&.5|8H4|8K8>B.RJ).""|6- M5DA%Z6@1?/B-
P\$A|@VE7B\$GB@>MB1WO0>2W?AVJ<.)2K.16K&%2">0B B/(EF2EV>'N#AYMJ:/HZA'NIB)&&91*>G_D#CX
M9E<9>L^X=|RT:X AC3PIEJU76+4(E"TYE%FX4 JI:F<%=5\$HCB?)@'BCA&I) M%6=9A^XD| RDZP(CRW1&G-2-
<3BE6%)F*MG2I)8EB,TD/QHER|GB2*7E\$=) MD*R&.&JYAT!|E).J1=8"D?#?'19:V'W.9*"-.SD6A8F+)XF#^4F(9FEX|IF46Y
M.^9(E7KBD8.BE+:4F87SA&KEAM5"D|^Y=VHB/H7&%OERFL?)AE^U3:OY4(OI M6|TXAV>YCLXID-
%6.HTY"8"@T*%F)R9@|^)E37(EQ))JWS% :G.@98\$|I9&EY<-6C'OB8 1.IL>E&|.6)|P>9|1Y)3MHZ%HZ9^Z|#
"&J#*4TF MXSZ#J:.)&DI0Q* NNG06REZ/ET>2*97SR9""^S:J1"YB8+ *3#BF97A*:0L M19?%\$1T,-*
:\$81*:>IQHUZ).VG8W6DA2FIQ29IOB9<4&D5<:A |:HS@!Y-! M.J1|6:;(9#' MBC BZG!C:AR/(9I-
D ^3BKJ|H02/CAJG>%|91EHEHWBG=XAR>FHJ*RD0 "F= MO/BF&S.>P3IL-
DE!AY.JJHJ|0M2DKAHP#ZIR(ZE@=GIPF)*EOJ1O=BAM#(P MIVJL-P.>84JH?EDV*D-
"C(&L"5IEK125S\$J2L"HW=|J)L48G.+HG|J4V4J4 M#4\$OO'HT23.H385|TE6J|@H%\$CG&NZ=E#!UE|I|
I^UOI|V%EO3#FM#CN=%)NA MG?J:|=.=/-LI%JHN6\$VI"A"!GNPZBF"R\FPUF*O&BNK^=J3|*R|RJG0|F/
M6&IR9*DTP:*8N"U*J8Z3A3|HHDSEJM5 H ^*K MH0ZZL42C)7&FLS6IM2-&C".+D):F*B&LD9|JY0:J2ZG:(>6)#\$+LS-
K=E+; MEE1\$3>M: ?^*&SPKL_0Z1(@:+V!+F\$3:2&E*MT%9;|F(M/WTLI-FL16ZN!|\$
MM|WZC|*-21#HG:.\$A|KJ|\$5S/RSCMV\$9G12NJC:O:O:NB/W ML|B4.C87O:0|0WM;7N5OO3LI2X&|O:Y:N/#IB73K_|
<2+S'>Z7%JWCYJF|= MB:.E\$Y%92Z:N6Q:..2U3Q.:1863Z!>K '6+|AK8K1|JOB>|VZ|XT2L"WI;^&
M8SL#RL#2^TYK|2|/\$<'T).3L6<\$!#.#.:8Y|11F9=;B..V:%)|C-C>@.C@* M?.+CZL_Q1" M7(V,":HQI):V"KP?
G&+DR,%0|"GC&YOG>TNO^D|J|XS4H|_4Q MH2E,B)(C)|JOB4?+R|03N\,R|TK%KX5)()/(LB/^)PP;.B\$&. ?CE/ !I:!
<+S&%;O*Z8JQ((HW0*PZ|Z7P)*:GRR\$ M>ZJ|HURKN\$K1?O2- PB5HOFB#QJ/6P MKK5H^F>S,??O4N)S+I:.PXV+
MI-S*B:R?'9=)J0C>)?-REK|NXPXL L^|(O)M7PKMRS-0T@XDG|BU|S+D.R> M\$-MQ:SQ7QCS3#NIR.Q H4Q*9OC.
TT3|-S.D#@X (H^RBS/>9/#O-B?0)?- MJIR ^"N4L^K/N>-.YMS,"ZS.'YU=T7S0TE?)|M/0?+\$+.CYS1X|S2M#0S^CR1
M5!QRDRQ|9MR|Y0/2.>T2>C72)!W+C7K2>7SS)MFS#MID>-6VEYT^RC MTVUM\$E9|U>_ VT^J|U54WU(
:UGG=TM=&<.%LO\$QM3=6.UA0U61SM0&Z-V#P= MUUBMJ)=RW!=VD|6HR:|VI#M
MR#8#SY2MW+FMK8RCV:J+V1H9V|^!QA_XV0X4VJ?M/8H=W')RVJKUW7%GR<7| MOX"|.0H|W @+>'Y+6#>B|
<:/S/|8L?+N H|J|\$DM*. M|M:A=XZWMRHYMATU.(FA7I|^)(. '>O5I-7H8"4|4TSD@D?N XCN4M7>4=
MKL:F'6|9#IOS#=#2\$=.1>O-TB#>.*NG0K3N778N.6#>8Y#M:F|QC>")!>> M=F!%GD?
V34".2#IH|K|0'@&\$:NBH+>5|WN8CSN5O%>>/GKQ:[N6\$: ^+ ". ^":
M/>:B5:./O.1IOJ2)S.:+GA|:O^>0|IZ^W<=2ZSJLZ!(&Z*1A?0M>3G./H
M;=3IBGKHx|WDN_XPKUU!HL|DP|J0N|JIDZ1?2WLK)SL>.|J|S:CHC3K^Y7D M/"3HGH|H1ZOAP.|FK.Y;QE|L'E|@/|
|/\$XA|L3VE%'O*FYYSTUYQMYZ>N5|A MNZ|K&Q@PLJSM^U+:T.+M^X|CC+|L.OSO8T?LCM1=SVY*T0Y5@%?MUIY5
(|N M|I|M=|Z|I|OLAWN|SE&%18%.'AK|K|PX3P+E'K%AGE-|F%0:NB|IA|A|O M| |I^F|Q\$!|?2MVL%&_SBHSLE2|/#
1|006|4C.K?TJ|3NRC'RG|2T9Q(8#\$ O MHJOH.J 'Z1^BAPO|7I|?R^YID.BU>|*^HY#9"4(D*EBKOY"Z
M|FA |MB>Z4XO=>G.FP- |S^?|Q(+YZE|XM NF P>ZP\$5|O+R|?KBT)W=%DI_M|=S:|&X?'U_G5.O|X_O2ZDN|8?
[:EY|U46Z|4UEV)|FGX|OANO&NODV;O M*1?Z"R?|A7>=!^O^#./|V6K||\$?X/ZN|Y=JY6XZ|SX*N'U?4'|6C|(^=+3
M)952^(:?|D3|ZU?H&|>G9#O^"!>|5UMGUC/@:D/1&).URM5R|???| (=+ 3
M7RBZAJ9/_JA_JBW ^9'BZX&C_%7S^M.O^|:A^Y ^V+ F@G_|=7|^DQ-". M| M|!1 7(@@4&&&@P8.&"R9DN-
AP@NX)\$ZD6-'B18P9-6X|0># \$1X|@W8< M&9*D2)0G59HDL-'ERXH(9ZT"=|G3Z!|A>)*R;+DT:)(5RHU
MFM3IB:%1I4ZE6M7|5:Q9M6|5VG3I4Z|AF8X%2_KV!; 6?5OA|M_!&T(D M+ORA|9H+>2*L#1.V:=#+=2ZH29VF|?
^9V&5J1|C=H/(<(X+\$W|YU:| FDY-6O M9|>O4_3Z,W'= O>OL7G|_7GYR^/_W|_!0P|!)"I^WXZ<\$#\$2TLP- 8+
ME)"L|RLD:|&|XP0P|DL|)"H#4.|Z4.2:~/MO-Y05#% %HGS:3CD8H1OOIX2
MY!|"JZ*33<4<>>V2N1*UN%+I|(L|T|LC|.O02+20K&U|O)I64.DHJH;1RR2NG MU.O)B:3\$|LN6N+RL2C#)#%-:
\$.TDPVU|0K32"|I_|.JE:|4|=?GOQN|GY M|+.XAF12SL<(-)2SLOQY%*|Z1|JK+M'MZNN3@7+))23#|5|"(W+35PT|4& M:-
(30SLME=3_44|5-46=71B2"F6U.+N(C6(6X!_%?ACD-?=>^20U=3WY'I3|GADE%8RHUW598 AI|!O&UN> M@::Z:M%
<3AEKEZC6^FN=50X:;. P%9O|D.|VEVOWU":;6G9ONIM_[SD1I)H M@XM&>. ^#HUZNUX>=MDGBB@N_V|"..?

Y.X\4W!A8%NFNU>W*KQZ:5O>.:M #V M/'\$ 6O?@?61O:1/#8\QIQ>% 'O'/YY3 _\NZ&Y\XC\?L?'OS++0^ +?->46
M/3>5:G15.J#(!KA FC607ML\B@3?0\3R93\W&SR:L\+G./4*"UWJ^6 ")14K
MR""%0)19DH9@vV* CO5\!)+2AOV3(*I#=-./"-R*"G7HM1H^%\$%\$!\! Y.&B^ M0"7-A#Q23\K8@S_Z0=%^B:L?
X:1HQ6>)3HBQ(V(7+>3#-F4/C&OR8AEC-49+ M*9""5C)C4+;X1N?1<(TC:B-
K.\$BP\OVQ\TJ.FGI.Y9XE\O)OFH+C40901T3Z M<8Y2\MXB4Y5(2'+IA_RQ'AHE%,F-3-*136-A(2F#R<^@+X\RI\J
@KW4A.=DG M?EB.(A6O^#Y6RB\J3+P1E+;7GR32*49,+LF4O*V1)\H(F""RY41\$-4OA+;ZY39A+ 7&
ZN0+42)MFML\91,+)\L+O5*@\L"3H*B<%PC:4Z%# M,2\$Z4YB\IC*>&\5< T6H0H!\.U"HIREL^1:G\)&JS;1R: M'3^W6:
<4.E.D.\4(1\$TCOHKVVY TY>E5:/JS"(T0QK%:%%7U!\-IM1.)N7C M\ESZ-
&@E!\DFML.H4\SI0@V:U1VC:J%*]2A2C"DE\QPSK#K\Z5\#D=\$\J5*M4 M:UE6N*K-@.Y\$JU!.>E>]4?.I4GM02E)
(\V:\$DX8K2M/?\J9 L65285E;\$8. M\JYEV/G8NH%1L6SU70#0V\B=(=*I3 ^NW6KY2JZ*M8D\$KAB89:G.BEAU- V)9
MNU:5JO:U:OW8;!T4R9A*MK(G\U\''8 L2SDH3I9\[\%8C65P3B\JFKOU6H;AW3
M6Z%>DKF.=6Y@(\AM= T"RNK;J8R\LEV=-)"/R\$U?:\$L\6E>F\Z\FFE4F^" O> M='(7.?<
Z3+W3@>]:Z%H:MN^T0(K&:7\A-+WQ8AP\TC>?AX7P<(\4E%#2N\B M;E=<] 7P?""<4PGWY:H5YF(…R3Y-O.
EUA*KYV4Q:5W<8&"2 MN)D?E@MF.WP8&<^4QA2ZZ(V=XF\$0\|A7Y=Q?CBN"5 _&>&4X,>^2&6:D81K9
MESYN\$F:#S\$XI- > 6/X8E=-2OBM\&6#('ROWLO\LD9D0U\DI!N5ZT>OF%JO7
M\JNX#DE/' -8P6QBZ0M\+G=)'9R+U>NM]:*8MS1H,NW4=>Y4M)3SN>:RMAG2 MU"K1#?
T,2D.O\!F9KO&E(XSHFP85T*%C(J+M.O%0?TEV\;STI#\+2NRLV,5R MEG5Z2<113V-RU"B1X*
[ADFNBF\AH\@MXU\$5.MW8KD\MBP11TM_2Q<5_<1D\N MTV7C)\0(VV6Y3\K&9JEU#2LX8S
MO>>,U2]:^MO^5:=@+-AOC^V:W\+>KZ'-K>U.:P3@|4\$=JUL-[W@':\X1W\F# M="AP1")\F0A\$.:J/" <7.ZA0N?
S_[G=K+H%:1Z#4>9:R?VH!:3TE4P@X@RCG.-G\^K= YWW'Q.:|'2TN"S'A6RK " *K\TQ-F>X\$0^OB8KK:G?N_CU
M91K^+P^V?/P:T.^:YC"FG\354BOWP.^E^F2 ^#\$WR\W-.\^TR\=N=Y^/,@ M)EY>.>8?)\$O>(\.5O=
M\KIT9WZJJ^=]9%6V\)\%U:;7S\TQ:AU1-/XMUG M_WSZB@GY\|C7MW>\$3?V\&OPO:BLKN9R\?XE"W\^O=/Q-
"C7ZQB: ^#.?QO' MUBOH\^+O@TYP7?(\S% + 80LKGSW8%._J6L^R2\9: D^2NU D0Y&GK ^CN+ MW^JSCYO [P
[<|L> &_#CR\RHDO:!\!>0=3\J V'N YL"N""0_#0V #.) MOHH, (@=%\S"FSS:2^Q0C\|JZF\!\\$Q\J&& OWL2NXM!'O\]
(+I U<"O I*^ M#^P^0%LUI\,+|0D_K*D\;#/"(VP^%HRSN/..V8 K\I3\!P_G,62H4F&.:E\|JK/74\|8HTBIC!\+]*.BK\$D*
(TF!+Z")U:&\K>\$Z:+6T\JFK+A:RX\|G%\R(FTFUPTIC_\$G*,LEW\$LH^VC-@ M!\\$H!=,>R5(HB&4O4G!
<89,NVS(F;0:6F,I.7+&J\!":\|@JRV1,N(D<5 M\$CZ-Y\$QO3\$K#/, X&4V3N,I@N4?%7,P:>9"/W,S9H#BZ'*/\$S,
<1A">NW,M9 M^B_O&1.?""D6B59?S.\43.Y&3,J\J2(G(U:22AZ;3*VRFH\Q.G.F9 MK8LAO\08X_0600Q\NE/PB-
Z..X\Y2Z@YPAVHC*:US0PM^&YWE\ZA2R/Z\| MW.PIXQE+Q S+:@%0L^PFS?3 E\$O^C.&4|M/PU=4E
UU.OK047=T%TEI%5E5?#, M4"UUU>0\$4A\$|I#735++\U4\51YKRU5XM,JQI4UO15O>"U\$5UU'&QTC155M:L
M'<=|HLB\$S,\YT\N25D'=/J^R5E3=1J\$,UBRU5_&D4H(\$UQOE37)=3,|A\01Q M.FC=%W>=UMN,5WD-
U62U&6X%E8#1>N/<2D55BB'=KMV3 7 M!5%|A9/Y#D\U.P3Q10G;5L%%"A\$(E):5: V9)^YU567\2FPQ=OHV=? (M166
M:; "91:|A*|M>--QE?5OD HW >5R\$C4_FFES5+5V\#4K I+!'JEC9D=U@ 370 M=:L:2\|R/G=7&:=R>--
VN+47P6MVP51E@=MQR=SLG%.@:C:|5A.'VX MC1:@:..(X7#NR7>2\G6NG7:H(4Q':6OS14=Z\51BF-
!1+K:6\J4WW^V4Z\U! MLF6N\|:U?#|G.?74PD3:D+1@FF5:ED2NW14/T6W?Q5V<@L4F!99? M6LXDWA?|0"M@!\|ZM&?
7A&F7@?&M:NU<:/DI M&\ZF#M:8MWUBC\EA=^%A(#OAU.5>+38)R \$ Y/7M,Q\YSTC)B:@5YU> M?
H(0):3B.I+@Z=IB%<9 O^Q:T#/B:UE:."MC+3KC>#0E*?93\^&X3+DQ5AU M8Q/^8C^#63GNS_15Y'N%9-
I3X\J\$8LR+=30N5S56J<|08/I Y'W\$8V #XCD^ M29TC8AH6Y2X\UKO4VPRVW3\GT\NOS:..95GF7#W^DJT
JNN =M\$%W6+E3&MB VM1Y6Y26>YC,LY@W48S/NMEBV
M%EL&V4KMHA#FW3BE\$X,6*9G*\$XEPC9:3:Y3#N3EXTN71\$)T10R^NB.F@*QD>#=L\|P6F@Z MT>FM0%5EQC-
N'BSYRK(=J>C=Y<1Q9F.!F>E6_FA""(E2+M\J3)>F(=FJM)3O)
M\|=B9FDC"QLBH\BB:XNDT4>NY"6IP.L7:K:ZNS@FC5E=: M>^F.)BA>.:QUC63?
L^SKL^OI6J8^6N*XN.9RN>X#KLHE_7EFL24UORSNNLPFC3+ARZVVL\I^R\|S\$S85HK8 M3HG95HG:/DW9SFW:
|K@2OFR=|=X3N.V1\$.Z/(\@UFW:1F\JU?YJ%>:4*P;\$I_Q^/T(\$%^7B*1Q'=|QRO9PYF)*^GXRUIY\$B\|RIC8*
MGJ0Z(U\|R)D=2*OOO%\?KTA:AQ^93UABZ\|L\|R+=|R+N_R47\|RV.IG%P\|*LXY M+S\|S-\$\|S-5\|SM\|J."|P D<0U-
K\|S\|S/=|S_)D&6VLAO_.\$\|UD MC%CD\|MN85R=BE_12R:Y W_D\$|4=X_>(1/\^LM.GORPVM"K)UU2(6?>(\JO>(\NOR9VS
M\|69BWV8'^""%I>RJD\6 >)(O>9_>9O#ZF:_L+FR(QX7:4CWF9GWF:GR|=
MRW8X_W=64D)H3A":Z6:#WJA'WJB%RE*KL9:(T-R2:I*JG?WJHC_HWMF2D MUGFKIQBE/|?
VB"6I\WJO_WJPOT^4)B(%5J.DLAZ#WNU7WNV; M2U>H#+>_
MSWK==%:8'3K5Z_@TK=BS9LF/HDVK=BW;MF\?PHTK=R\=NG:OXLVK=R_?OG\O'A6*M5#A#AHH,-
%PZ,>+BQCW_*FRZ0.KD\J6A7GZ:V>EFR90_0VX:87+HTJ9/H_L
MK7HUZ\|N7\..+7LV[=JV:^\K3NLX\2>S/^+=PW\>#%>X>^JGPY\^6\339\]
M+GTZ\>K6KV\|KGT\|^\>OX./+WZ\|P.'&SP-|:U\|?7N?^+% -GR?GT\|O' M2C\B@OW^ P,8H(# \$EB@@0A!"R-
Z&%0\G5G(8: M>@ MAQ^"&*(Y)8HHDGHIBBBBO21J&\$%<+XHHNPNTGAA4E\U-E\|FNW(68^>T<>B
MD\$,26:211R*9I))+,MFDDUO96&.,4LX8I953TI05AUMR"=637X(9IACDEFF MF6>BF:::
(V'99I5N4AGGE<|I\61^\.*YYT^YAG_P9I_AJHH(,26\JBAAR*: M*%P#R
GGG(V^&6FC6G99Z8:*8\J\IIMRV\FGGX\::H"0DQ\H\8ZB.EB=>K+*
MYYYV\@J\KCZ+26\NMM^*:JZZ\|MKK0J=*FRIJ0Y\ J66(GN5K\LRVZRSST(; MK.33@D>LL-
=:F^UPOF:5H\|< ZMBGK+)>26ZZYYZ*:KKKKL MON1<%J6ZR\|V ZW M:K+W1N6NOOORVZ^ P(<<)|HQ\$OOO
6C:N^WXH\|:L.OZBBPO\|37+%'%V.< ML6P(P\|OQP1X392^^(VMKK?327:=(M\|OSTUVWW7= _Q':6>CNZUN.)-
J\|WXWAZ\ 3:'BU->N>678YZYN7ROW?FD2@MN\^_.|Z>YZ:>C
MGKKJ\ _I.>N'Q:YY\VR7KOMM^>N^X+OQXX\(+Y;KP7G>UN_ "(Y^\\LO' M\|KOOSOLE^&^S*E^|J|=CG\WV8GD.??
>!\^0VXZ:..|G\VYZ.?OOKKLW\|0\^ # M& \T&K9?O_WWXY\ ZMX\|ZW\79..>-'1\$+>: #G\|L_?M>Q_XW/^HE,((2
MGA@!2MH,08N4\$KA*Y_#0F?!\#X(PA"(<(:OPR+).?"!5"\$A"UOHPA?"\%#P MRZ\!4LA! -HGACK<(0\]
[Z..DF7"&!\\$BA"@F%\J(1YH=*7"(3F^A\$N_OOBL\$3 M8 = 9);W\$.R)6MPB%\|OHQ:PA\83^ (V(1\|B;-WTQC6\|<(OO:B
LA3NE_-Q3? MM\82\|S?B,8\|ZW&.,Q?@BKY0Q7V\AU*-OP,=#(C*1BI0@#7T"R_!"4F=@\$=8B M*VG)2V*2?6)\9#-
Z)5L93*4HAPE*:UWK4?<728X8VP\|E#*5\|REK\|W@D\| M>11.!O*.Q9HE+WOIRU\2.)
(XU\|W3@G.8R\|SFT94(SFM*IPGOX\| MEC:1.Y_ZW"< F75=-A:OGG_L)T\$+M"#*N\|:AEG81#J\T(="*)B_F@5S2?1
MBV\|THQ\|5UOPVZM&\|@C2DGO(F145\|TLB-*5FFIU*6^K2E\|)41:I_GM-2@!TL80N+|4RWUM2PBETL8T\|M\9"-K*2Q>-
_>339RV(V MLT\|:6P\|H(WO.(%557&:\|SHK=0-TLO>|OKWC%-Y;WRG2\|B225^N(WO_H% MD2#WZ\ _O@_8
LP@0ML8.R\|L_*7C"#9:?!D.XPA(NC2,8M:\|.(7PSC&.IXQC6L